The 39 references in paper А. Комаров Л., А. Комарова Л. (2013) “«СТАРЫЕ» И «НОВЫЕ» ВОЗМОЖНОСТИ ПРОФИЛАКТИКИ ИНСУЛЬТА У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ” / spz:neicon:aterotromboz:y:2013:i:1:p:44-52

1
Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)//European Heart Journal. 2010. No 31. Р. 2369–2429.
(check this in PDF content)
2
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation. A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association//Stroke. 2012. DOI: 10.1161/ STR.0b013e318266722a.
(check this in PDF content)
3
2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association// European Heart Journal. 2012. No 33. Р. 2719–2747.
(check this in PDF content)
4
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [published correction appears//Arch Intern Med. 1994. No 154. Р. 2254; Arch Intern Med. 1994. No 154. Р. 1449–1457.
(check this in PDF content)
5
White H. D., Gruber M., Feyzi J., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V//Arch Intern Med. 2007. Feb. 12. No 167 (3). Р. 239–245.
(check this in PDF content)
6
Connolly S. J., Ezekowitz M. D., Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med. 2009. No 361. Р. 1139–1151.
(check this in PDF content)
7
Patel M. R., Mahaffey K. W., Garg J., et al. ROCKET AF Investigators. Rivaroxaban vs. warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011. No 365. Р. 883–891.
(check this in PDF content)
8
Granger C. B., Alexander J. H., McMurray J. J., et al. ARISTOTLE Committees and Investigators. Apixaban vs. warfarin in patients with atrial fibrillation. N Engl J Med. 2011. No 365. Р. 981–992.
(check this in PDF content)
9
Wallentin L., Yusuf S., Ezekowitz M. D., et al. Efficacy and safety of dabigatran compared with warfarin at diff erent levels of international normalised ratio control for stroke prevention in atrial fi brillation: an analysis of the RE-LY trial// Lancet. 2010. No 376. Р. 975–983.
(check this in PDF content)
10
Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines//CHEST. 2012. No 141 (2) (Suppl). Р. e44S–e88S.
(check this in PDF content)
11
Whitlon D. S., Sadowski J. A., Suttie J. W. Mechanism of coumarin action: signifi cance of vitamin K epoxide reductase inhibition. Biochemistry. 1978. No 17 (8). Р. 1371–1377.
(check this in PDF content)
12
Cannegieter S. C., Rosendaal F. R., Wintzen A. R., v an der Meer F. J., Vandenbroucke J. P., Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995. No 333 (1). Р. 11–17.
(check this in PDF content)
13
Abdelhafi z A. H., Wheeldon N. M. Results of an open-label, prospective study of anticoagulant therapy for atrial fi brillation in an outpatient anticoagulation clinic. Clin Ther. 2004. No 26 (9). Р.
(check this in PDF content)
14
0–1478. 14. Veeger N. J. G.M., Piersma-Wichers M., Tijssen J. G. P., Hillege H. L., van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venousthromboembolism//Br J Haematol. 2005. No 128 (4). Р. 513–519.
(check this in PDF content)
15
Sudlow M., Thomson R., Thwaites B., et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community//Lancet, 1998. No 352. Р. 1167–71.
(check this in PDF content)
16
Brass L. M., Krumholz H. M., Scinto J. M., et al. Warfarin use among patients with atrial fibrillation// Stroke, 1997. No 28. Р. 2382–2389.
(check this in PDF content)
17
Go A. S., Hylek E. M., Borowsky L. H., et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study// Ann Intern Med. 1999. No 131. Р. 927–934.
(check this in PDF content)
18
Эрлих А. Д., Давыденко М. Н., Маслова Е. С., Саляхова Т. Ю. Мерцательная аритмия (фибрилляция предсердий) и антикоагулянтная терапия при ней в московской городской больнице. Однодневный скрининг. http://www.athero.ru/ AF-hosp_cross_sect-web.htm.
(check this in PDF content)
19
Witt D. M., Delate T., Garcia D. A., et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding//Arch Intern Med.
(check this in PDF content)
20
2. Oct. 22. No 172 (19). Р. 1484–1491. 20. Blackshear J. L., Odell J. A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation//Ann Thorac Surg. 1996. No 61. Р. 755–759.
(check this in PDF content)
21
Атьков О. Ю., Атауллаханова Д. М., Быкова Е. С. Возможности чреспищеводной эхокардиографии в диагностике тромбоза ушка левого предсердия при мерцательной аритмии//Кардиология. 1999. No 12. Т. 39. С. 58–63.
(check this in PDF content)
22
Dawson A. G., Asopa S., Dunning J. Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? Interactive CardioVascular and Thoracic Surgery 10. 2010. Р. 306–311.
(check this in PDF content)
23
Healey J. S., Crystal E., Lamy A., et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke//Am Heart J 2005. No 150. Р. 288–293.
(check this in PDF content)
24
Salzberg S. P., Plass A., Emmert M. Y., et al. Left atrial appendage clip occlusion: early clinical results//J Thorac Cardiovasc Surg. 2010. No 139. Р. 1269–1274.
(check this in PDF content)
25
Ailawadi G., Gerdisch M. W., Harvey R. L., et al. Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial//J Thorac Cardiovasc Surg. 2011. No 142. Р. 1002–9, 1009, e1.
(check this in PDF content)
26
Alli O., Holmes D. R. Left Atrial Appendage Occlusion for Stroke Prevention Curr Probl Cardiol 2012. No 37. Р. 405–441.
(check this in PDF content)
27
Nietlispach F., Gloekler S., Khattab A. et al. Percutaneous left atrial appendage closure// European Geriatric Medicine 3. 2012. Р. 308–311.
(check this in PDF content)
28
Ostermayer S. H., Reisman M., Kramer P. H. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high risk patients with non rheumatic atrial fi brillation: results from the international multicenter feasibility trials//J Am Card Coll Cardiol. 2005. No 46. Р. 9–14.
(check this in PDF content)
29
Sievert H., Lesh M. D., Trepels T., et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation – early clinical experience// Circulation. 2002. No 105. Р. 1887–1889.
(check this in PDF content)
30
Hanna I. R., Kolm P., Martin R., Reisman M., Gray W., Block P. C. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO) six-month echocardiographic follow-up//J Am Coll Cardiol. 2004. No 43. Р. 1868–1872.
(check this in PDF content)
31
Fountain R. B., Holmes D. R., Chandrasekaran K., et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial//Am Heart J. 2006. No 151. Р. 956–961.
(check this in PDF content)
32
Sick P. B., Schuler G., Hauptmann K. E., et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation//J Am Coll Cardiol. 2007. No 49. Р. 1490–95.
(check this in PDF content)
33
El-Chami M. F., Grow P., Eilen D., et al. Clinical outcomes three years after PLAATO implantation// Catheter Cardiovasc Interv. 2007. No 69. No 704–707.
(check this in PDF content)
34
Holmes D. R., Reddy V. Y., Turi Z. G. et al for the PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial// Lancet. 2009. No 374. Р. 534–542.
(check this in PDF content)
35
Reddy V. Y., Doshi Sh. K., Sievert H., et al on behalf of the PROTECT AF Investigators. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Followup of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial//Circulation. 2013. No 127. Р. 720–729.
(check this in PDF content)
36
Reddy V. Y., Holmes D., Doshi Sh. K., at al. Safety of Percutaneous Left Atrial Appendage Closure Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry// Circulation. 2011. No 123. Р. 417–424.
(check this in PDF content)
37
http://clinicaltrials.gov/show/NCT01182441
(check this in PDF content)
38
http://www.theheart.org/article/1515107. do?utm_medium=email&utm_source=20130404_ monthly_mostPopular&utm_campaign=newsletter
(check this in PDF content)
39
http://www.theheart.org/columns/trialsand-fibrillations-with-dr-john-mandrola/ esc-2012-is-left-atrial-appendage-closure-thetherapy-of-choice-of-3.do
(check this in PDF content)